SML3532
BAY-091
≥98% (HPLC)
别名:
(R)-2-(3-Cyano-2-(2′-fluoro-3′-methylbiphenyl-4-yl)-1,7-naphthyridin-4-ylamino)butanoic acid, BAY 091, BAY091
InChI
1S/C26H21FN4O2/c1-3-21(26(32)33)30-25-19-11-12-29-14-22(19)31-24(20(25)13-28)17-9-7-16(8-10-17)18-6-4-5-15(2)23(18)27/h4-12,14,21H,3H2,1-2H3,(H,30,31)(H,32,33)/t21-/m1/s1
InChI key
DVIVLYHDLNAXAT-OAQYLSRUSA-N
SMILES string
N#CC1=C(N=C2C=NC=CC2=C1N[C@H](CC)C(O)=O)C3=CC=C(C=C3)C4=C(C(C)=CC=C4)F
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
Quality Level
Biochem/physiol Actions
BAY-091 is a potent and highly selective PIP4K2A inhibitor (IC50 = 1.3/2.6 nM with 10/250 μM [ATP] by ADP-Glo, 8.5/16.4 nM with 10 μM/2 mM [ATP] by HTRF) with good cellular permeability (target engagement EC50 = 1.1 μM/intact cells vs 1.8 μM/cell lysate by CETSA) and no significant off-target activity as assessed by a 373-kinase panel (<60% inhibition at 1 μM).
Potent and highly selective PIP4K2A inhibitor with good cellular permeability and no significant off-target activity.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Lars Wortmann et al.
Journal of medicinal chemistry, 64(21), 15883-15911 (2021-10-27)
PIP4K2A is an insufficiently studied type II lipid kinase that catalyzes the conversion of phosphatidylinositol-5-phosphate (PI5P) into phosphatidylinositol 4,5-bisphosphate (PI4,5P2). The involvement of PIP4K2A/B in cancer has been suggested, particularly in the context of p53 mutant/null tumors. PIP4K2A/B depletion has
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持